Granzyne Activity in the Inflamed Lung Is Not Controlled by Endogenous Serine Proteinase Inhibitors

Guy M. Tremblay, Angela M. Wolbink, Yvon Cormier and C. Erik Hack

*J Immunol* 2000; 165:3966-3969; doi: 10.4049/jimmunol.165.7.3966
http://www.jimmunol.org/content/165/7/3966

---

**References**

This article cites 24 articles, 8 of which you can access for free at:
http://www.jimmunol.org/content/165/7/3966.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Granzyne Activity in the Inflamed Lung Is Not Controlled by Endogenous Serine Proteinase Inhibitors\textsuperscript{1}

Guy M. Tremblay,\textsuperscript{2*} Angela M. Wolbink,\textsuperscript{†} Yvon Cormier,\textsuperscript{*} and C. Erik Hack\textsuperscript{†‡}

Numerous lung diseases, such as hypersensitivity pneumonitis (HP), are characterized by the presence of activated alveolar CTL and NK cells. Since these cells produce granzymes, granzyme A and B levels in bronchoalveolar lavage (BAL) fluids from 14 normal subjects and 12 patients with HP were measured by ELISA. Median (range) BAL granzyme A and B levels were 4 (0–37) and 0 (0–6) pg/ml in normal subjects. BAL granzyme levels were significantly higher in HP patients, being at 74 (0–1889) and 10 (0–78) pg/ml for granzymes A and B, respectively. In vitro, neither of the three main serine protease inhibitors of the lung, namely α\textsubscript{1}-antitrypsin, secretory leukocyte protease inhibitor, and elafin, showed any effect on granzyme A or B activity. In addition, granzyme A was shown to be fully active in BAL fluids. Hence, these data show that granzyme activity may be poorly controlled by protease inhibitors in inflamed tissues. Thus, granzymes could contribute to tissue remodeling and inflammation characterizing HP. The Journal of Immunology, 2000, 165: 3966–3969.

\textsuperscript{*}Centre de Recherche, Hôpital Laval, Institut Universitaire de Cardiologie et de Pneumologie de l’Université Laval, Sainte-Foy (Québec), Canada; \textsuperscript{†}Central Laboratory of The Netherlands Red Cross Blood Transfusion Services, Amsterdam, The Netherlands; and \textsuperscript{‡}Department of Clinical Chemistry, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands

Received for publication February 22, 2000. Accepted for publication July 12, 2000.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertised in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

\textsuperscript{1} This work was supported by Bayer/Canadian Red Cross Society Research and Development Fund Grant 9715, and Subvention d’Établissement de Jeune Chercheur du Fonds de la Recherche en Santé du Québec.

Address correspondence and reprint requests to Dr. Guy M. Tremblay, Hôpital Laval, Room M2691, 2725 chemin Sainte-Foy, Sainte-Foy, Québec, Canada G1V 4G5. E-mail address: guy.tremblay@med.ulaval.ca

\textsuperscript{2} Abbreviations used in this paper: HP, hypersensitivity pneumonitis; BAL, bronchoalveolar lavage; SLPI, secretory leukocyte protease inhibitor.

Copyright © 2000 by The American Association of Immunologists 0022-1767/00/$02.00
Inhibition of granzymes by serine protease inhibitors and determination of active granzyme levels in BAL samples

Effect of serine protease inhibitors on granzyme A activity was done using a method based on the interaction of active granzyme A with antithrombin III (20). Briefly, granzyme A, purified as described previously (20), was bound to anti-granzyme A mAb-28 immobilized onto an ELISA plate at 3 ng/ml, and incubated with increasing concentrations of up to 10,000-fold molar excess of α1-antitrypsin (Calbiochem, La Jolla, CA), SLPI (R&D Systems, Minneapolis, MN), or elafin (Peptides International, Louisville, KY), with biotinylated antithrombin III in the presence of heparin. Bound biotinylated antithrombin III was detected with streptavidin-coupled polymerized HRP. Purified antithrombin III (Sigma-Aldrich Chemicals, St. Louis, MO) was tested as a positive control.

Effect of serine protease inhibitors on granzyme B activity was performed according to a protocol from Enzyme Systems Products (Livermore, CA). Briefly, granzyme B (Enzyme Systems Products) and inhibitors were resuspended in 100 mM Tris, 500 mM NaCl, pH 7.5, at a working concentration of 150 nM. Then, 5 pmol of granzyme B was incubated with 5, 20, or 80 pmol of α1-antitrypsin, SLPI, or elafin for 30 min at 37°C in a final volume of 50 μl. This volume was added to 150 μl of 270 μM BOC-Ala-Ala-Asp-S-Bzl (Enzyme Systems Products) in 200 mM HEPES, 300 mM NaCl, 1 mM EDTA, 0.05% (v/v) Triton X-100, pH 7, containing 410 μM of 5,5'-dithiobis(2-nitrobenzoic acid) (Ellman’s reagent). Kinetic changes in absorbance were measured at 405 nm with a THERMOmax microplate reader (Molecular Devices, Sunnyvale, CA).

These two methods for granzyme A and B activity were also used to determine the presence of active granzyme A and B concentrations in the BAL fluid samples.

Statistical analysis

BAL total and differential cell counts are expressed as mean ± SEM and were analyzed using a paired Student’s t test. Levels of granzymes A and B are expressed as median (range) and were analyzed by a Mann-Whitney test. Spearman’s coefficient of rank correlation was used to assess the degree of association between BAL cell numbers and serum granzyme levels. In all cases, p < 0.05 was considered as significant (21).

Results

BAL fluid cell numbers

BAL fluid recovery was similar for each group of subjects. Of the 300-ml instilled, 181 ± 21 and 170 ± 14 ml were recovered from normal and HP subjects, respectively. Total cell number in BAL fluid was 97.1 ± 12.2 × 10⁶ cells/ml for normal subjects. Cell number was significantly increased in HP patients to 785.3 ± 103.5 × 10⁶ cells/ml (t test, p = 0.0001). All BAL cell types were increased in HP patients compared with control subjects (Table I). Macrophages represented about 85% of BAL cells in normal subjects. In contrast, lymphocytes were the predominant cells (>60%) in HP patients.

BAL fluid granzyme levels

BAL fluids from normal subjects showed minimal levels of granzymes A and B (Figs. 1 and 2). In these subjects, the median (range) granzyme A and B concentrations were 4 (0–37) and 0 (0–6) pg/ml of BAL fluid, respectively. It is noteworthy that, of 14 normal subjects studied, 5 and 10 had no detectable levels of granzymes A and B, respectively.

BAL fluids from patients with HP contained 74 (0–1889) pg/ml of granzyme A (Fig. 1) and 10 (0–78) pg/ml of granzyme B (Fig. 2). These values were significantly higher than those of the normal subjects (Mann-Whitney test, p < 0.001 and p = 0.007 for granzymes A and B, respectively). Granzyme A and B levels were correlated with each other (r₅ = 0.69, p = 0.004). In addition, both granzyme levels were correlated with the number of lymphocytes/ml (r₅ = 0.794, p < 0.001 and r₅ = 0.735, p = 0.002 for granzymes A and B, respectively).

Serum concentrations of granzymes A and B

Granzymes A and B were only measured in serum from two normal and nine HP subjects; samples were not available from the other subjects. In the two normal subjects, concentrations of granzymes A and B were 37 and 134 pg/ml, and 10 and 13 pg/ml, respectively. In HP patients, serum levels of granzymes A and B were 50 (27–262) and 6 (4–368) pg/ml, respectively. These concentrations are similar to previously published serum concentrations of granzymes (3). There was no correlation between BAL and serum levels of granzymes A or B (Fig. 3).

Inhibition of granzymes A and B by serine protease inhibitors

Neither α1-antitrypsin, SLPI, nor elafin, even in molar excess, showed any inhibitory activity against granzyme A or B. To ensure that the three inhibitor preparations were fully active, they were shown to inhibit human sputum elastase (Elastin Products Company, Owensville, MO) using the chromogenic substrate N-methoxybenzyl-Ala-Ala-Pro-Val p-nitroanilide (Sigma-Aldrich Chemicals), according to a procedure described at www.elastin.com.

Table 1. BAL differential cell counts

<table>
<thead>
<tr>
<th></th>
<th>Normal Subjects</th>
<th>HP Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrophages</td>
<td>82.6 ± 12.4</td>
<td>214.9 ± 38.2*</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>11.8 ± 2.8</td>
<td>507.5 ± 100.2*</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>1.5 ± 0.7</td>
<td>47.0 ± 15.2*</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.6 ± 0.5</td>
<td>11.7 ± 3.9*</td>
</tr>
</tbody>
</table>

* Data are presented as thousands of cells/milliliter (mean ± SEM). *, Significantly different from normal subjects, p < 0.05 using a paired Student t test.

FIGURE 1. Median and individual values of granzyme A in BAL fluids (picograms/milliliter) for the two groups of subjects. *, Significantly different from control subjects (Mann-Whitney test, p = 0.0006).

FIGURE 2. Median and individual values of granzyme B in BAL fluids (picograms/milliliter) for the two groups of subjects. *, Significantly different from control subjects (Mann-Whitney test, p = 0.0072).
could be due to the lack of sensitivity of the esterolytic assay used to show any active granzyme B in BAL fluids, even in the samples with thrombin III in any of the BAL fluid samples. Finally, we were unable to measure complexes between granzyme A and its natural inhibitor anti-zyme A present in BAL fluid is fully active. Accordingly, we did not determine the levels of active granzyme A with a novel and more sensitive assay, which is based on the binding of antithrombin III to active granzyme A (6) and B (17), but are in accordance with those of one group that could inhibit granzyme A (18). Our results do not support this concept.

Having shown the presence of granzymes A and B in BAL fluid samples and that serine protease inhibitors, present in BAL fluid in vivo, do not inhibit both granzymes in vitro, we next addressed the question as to whether granzymes A and B in BAL fluids were active. Usually, the BLT assay is used to measure active granzyme A levels. However, in our hands, this assay has a sensitivity of about 3 ng/ml. Therefore, we determined the levels of active granzyme A with a novel and more sensitive assay, which is based on the binding of antithrombin III to active granzyme A in the presence of heparin (20). The sensitivity of this assay, as it was run, was approximately 50 pg/ml of active granzyme A. Since only seven HP patients had more than 50 pg/ml of granzyme A, as measured by ELISA, granzyme A activity was also determined in subjects with other lung conditions having high levels of granzyme for a total of 15 subjects. There was a highly significant correlation between BAL granzyme A levels determined by ELISA, on one hand, and active granzyme A levels, on the other (Fig. 4). The slope of the regression line was 0.962, a value quite close to 1. Taken together, these results show that all granzyme A present in BAL fluid is fully active. Accordingly, we did not measure complexes between granzyme A and its natural inhibitor antithrombin III in any of the BAL fluid samples. Finally, we were unable to show any active granzyme B in BAL fluids, even in the samples with the highest concentrations of this granzyme. However, this negative result could be due to the lack of sensitivity of the esterolytic assay used to detect granzyme B activity. Considering this lack of sensitivity, the presence of active granzyme B in BAL fluid samples cannot be ruled out.

**Discussion**

The four main observations of the present study are that 1) granzymes A and B are present and measurable in BAL fluids even in some normal subjects, 2) granzymes A and B are locally increased in BAL fluids in HP, a lymphocytic alveolitis, 3) granzymes are not inhibited by \( \alpha_1 \)-antitrypsin, SLPI, and elafin, and 4) granzyme A is fully active in BAL fluid.

Normal BAL fluid is characterized by a proportion of lymphocytes of 5–15% (22), which includes activated (23, 24) and granzyme B gene-expressing (14) lymphocytes. The presence of such activated alveolar lymphocytes in the normal setting could explain the presence of low levels of granzymes in some healthy subjects.

There was a correlation between BAL levels of granzymes A and B. This makes sense considering that both granzymes are stored in the same cytoplasmic granules and are released together following exocytosis (6, 25). The increase in granzyme concentrations in HP is more than likely locally derived since there was a correlation between granzyme A and B levels, on one hand, and lymphocyte numbers, on the other hand. Also, the fact that serum granzyme levels were within normal range in HP patients (except for one subject) and were not correlated to BAL levels supports the concept that granzyme release is restricted to the lung and that serum levels are probably not influenced by local lung production. Published normal plasmatic concentrations of granzymes A and B are 33.5 (1–121) and 11.5 (1–113) pg/ml, respectively (3). In contrast, circulating granzyme concentrations can increase well over 1000 pg/ml in patients with EBV or HIV-1 infection (3), or rheumatoid arthritis (5).

In vitro, we did not observe any significant inhibitory activity of \( \alpha_1 \)-antitrypsin, SLPI, or elafin on granzyme A or B. The present results, as well as previous results from our group (20), are in contradiction with those of others who have reported that \( \alpha_1 \)-antitrypsin inhibits both granzyme A (6) and B (17), but are in accordance with those of one group that was unable to substantiate the inhibition of granzyme B by \( \alpha_1 \)-antitrypsin (P. Bird, personal communication). Regarding SLPI and elafin, our results clearly show that they do not inhibit either granzyme A or B. Based on indirect observations, Cowan and colleagues suggested that elafin could inhibit granzyme A (18). Our results do not support this concept.

An important observation from the present study is that granzyme A activity strongly correlated with antigenic levels in BAL fluid, indicating that all granzyme A in the lung is active. In support for this, we did not measure a detectable inhibitory effect of \( \alpha_1 \)-antitrypsin, SLPI, or elafin, the main serine protease inhibitors in the lungs (15, 16), on granzyme A or B activity in vitro. We did not measure any active granzyme B in the BAL fluids tested. Considering the low concentrations of granzyme B in BAL fluids, the lack of sensitivity of the assay used to determined granzyme B activity, and that neither \( \alpha_1 \)-antitrypsin, nor SLPI, nor elafin inhibits granzyme B in vitro, the presence of active granzyme B in the alveolar space cannot be ruled out.
Beside \( \alpha_1 \)-antitrypsin, SLPI, and elafin, other serine protease inhibitors obviously do not contribute significantly to the inactivation of active granzyme A in the lung since this granzyme is fully active in BAL fluids. \( \alpha_2 \)-Macroglobulin, present in small concentration (0.01 \( \mu \)M) in the normal alveolar epithelial lining fluid (15), is reported to inhibit both granzymes A and B (6, 17). We recently showed that \( \alpha_2 \)-macroglobulin is a major inhibitor of granzyme A in the blood compartment (20), in which this inhibitor is present at much higher concentrations than in the alveolar space, i.e., 2.5–5 \( \mu \)M (15). The assay we used to determine granzyme A activity in the present study, based on the interaction of the protease with antithrombin III, is the same as we previously used to quantify the same activity in the blood (20). It is important to point out that such assay excludes the possibility that granzyme A is entrapped, and therefore inhibited, by \( \alpha_2 \)-macroglobulin (20), since entrapped proteases are not able to interact with high m.w. substrates such as antithrombin III in the case of granzyme A. Moreover, we have clearly shown that all granzyme A in BAL fluid is active. From this, we can conclude that \( \alpha_2 \)-macroglobulin does not play any important regulatory role in granzyme A activity in the lung alveolar space. \( \alpha_1 \)-Antichymotrypsin is also present in the alveolar space, but it does not inhibit granzyme A (6). Finally, protease inhibitor 9 (PI-9), a member of the OVA serpin family, is an efficient inhibitor of granzyme A, and this inhibitor is not secreted by cells and restricts its action to the cytoplasm of lymphocytes, protecting these cells from granzyme B-induced apoptosis (26).

The presence of increased levels of active granzyme A in the alveolar space in HP is of particular interest. Indeed, granzyme A stimulates the production of TNF-\( \alpha \), IL-6, and IL-8 (7, 8). These cytokines are important signal molecules coordinating the lung inflammatory and immune responses (27). Not surprisingly, BAL levels of these cytokines are increased in HP (28). Therefore, it is tempting to speculate that granzyme A contributes, at least in part, to their up-regulation. Moreover, being an IL-1\( \beta \)-converting enzyme (9), granzyme A could further contribute to the local inflammatory response characterizing HP. Last but not least, the proteolytic action of granzymes A and B on collagen and proteoglycans (10–12) may significantly contribute not only to tissue remodeling, but also to the migration of lymphocytes into the alveolar space in HP, perpetuating, therefore, the chronic state of this lung disease. It remains to clarify whether increased BAL levels of granzymes are specific to HP or if this is also a characteristic of other lymphocytic lung diseases.

In conclusion, we provide evidence that BAL fluid from patients with HP contains high levels of granzymes A and B that are not inhibited by the main serine protease inhibitors of the lung, and that granzyme A is fully active in the alveolar space. These data not only suggest that these proteases may contribute to the pathogenesis of HP, but also show that high concentrations of soluble active granzymes may occur locally in inflamed tissues.

Acknowledgments
We thank Dr. Phillip Bird from Monash Medical School (Victoria, Australia) for helpful discussion.

References